Johnston, Adam Comment on Effects of Tax Law Change on Health Fraud Settlement Costs
23 February 2018
Partners Pam Johnston and Fred Adam are quoted in a BNA Health Care Daily Report article, “Tax Law Change May Raise Health Fraud Settlement Costs,” about the possible effects of a change in the tax rules governing the deduction of health care fraud settlement amounts.
A provision of the new tax reform act, signed into law on Dec. 22, requires a settling agency, like the Department of Justice, to state what portion of a False Claim Act settlement can be deducted as a business expense because it qualifies as restitution. The tax provision also eliminates certain types of previously deductible expenses related to FCA settlements, like government investigation expenses and interest.
Johnston said the new deductibility rules will “materially affect negotiations with the DOJ” over FCA settlements because limiting the deduction of the settlement amount could make the settlement less attractive.
Adam said the new provision “increases costs for both sides, for taxpayers and for the government.”
Subscription required to read.
A provision of the new tax reform act, signed into law on Dec. 22, requires a settling agency, like the Department of Justice, to state what portion of a False Claim Act settlement can be deducted as a business expense because it qualifies as restitution. The tax provision also eliminates certain types of previously deductible expenses related to FCA settlements, like government investigation expenses and interest.
Johnston said the new deductibility rules will “materially affect negotiations with the DOJ” over FCA settlements because limiting the deduction of the settlement amount could make the settlement less attractive.
Adam said the new provision “increases costs for both sides, for taxpayers and for the government.”
Subscription required to read.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”